Pharm-Olam is now Allucent. Learn More

Request a Proposal  

Oncology & Hematology Clinical Development Solutions

Download the Fact Sheet

As an oncology focused CRO with 20+ years of experience in managing oncology and hematology trials, Pharm-Olam combines an understanding of clinical trial complexities with proven strategies encompassing agility, innovation, and flexibility, to ensure study goals are met in a timely and efficient manner. It is this approach that makes us the chosen partner for small to mid-size biopharma involved in Oncology and Hematology clinical research.


• Over 85% of our experience is with small & emerging biotech!
• Over 25% of our study experience in last 5 years was in oncology and hematology indications

Full Clinical Development Services


Combining Scientific & Operational Expertise

Therapeutic alignment of project teams capitalizes on individual and organizational oncology and hematology experience
to provide the highest quality delivery.

• 88% of Pharm-Olam PM’s have oncology experience of which 48% are experienced in hematological malignancies
• 83% of Pharm-Olam CRA’s have oncology experience of which 39% are experienced in hematological malignancies

Rapid Deployment & Global Reach

Pharm-Olam provides global solutions for oncology and hematology clinical research programs across 60+ countries. We
help our Sponsors rapidly deploy their studies and maximize the subject recruitment period to deliver on-time and on budget
through our global reach and local insights.


Download the Fact Sheet

Therapeutic Expertise You Can Depend On

Pharm-Olam has supported over 100 oncology trials including 16 product approvals. Our extensive experience in the conduct
of trials in both solid and liquid tumours using NCE’s, biologics, cell and gene therapies, and immuno-oncology therapies,
provides a significant advantage in proven strategic planning, regulatory guidance, and successful clinical trial execution.

Extensive Oncology & HematologyResearch Experience

• Brain
• Breast
• Colorectal
• Heptocellular
• Leukemia
• Lung
• Lymphoma
• Myelofibrosis
• Myeloma
• Pancreatic
• Prostate
• Solid Tumours



Expedited Early Phase

With over 50% of PM’s and over 60% of CRA’s at Pharm-Olam experienced in early phase oncology trials including complex adaptive designs and FIH trials, and with a specialization in early phase hematology-oncology research, including leukemia, lymphoma, and myeloma, we are ideally positioned to expedite your next Phase I-II trial.

Immuno-oncology Drive

Pharm-Olam’s immuno-oncology (I-O) experience spans a variety of novel therapy types including monoclonal antibodies, immune checkpoint inhibitors, cell and gene therapies, GMO, cytokines, and cancer vaccines. As advancements in I-O therapies continues faster than ever Pharm-Olam looks to drive this area of research forward and bring these complex treatments to the patients in need.

Advantageous Site & Vendor Relationships

Pharm-Olam has an established site network with leading oncology sites as well as advantageous vendor relationships and optimized processes for specialty labs (biomarkers, tumor biopsy, pharmacokinetics [PK] etc.) and central reading (ECG, images) which augment the full service offering from Pharm-Olam to provide a near seamless trial experience.

Hematology Expertise

Our deep expertise in hematology encompasses liquid tumors, autoimmune hematological diseases, and hematological rare diseases. Having supported trials in idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and rare conditions such as myelofibrosis, we recognize the complexities of this research and offer the solutions and expertise needed to deliver on time, at the highest possible quality.

How can we help you create a healthier world?

Talk to one of our experts today.